| ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. Co.'s lead product candidate includes AM0010, a drug that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma and chemotherapy. Co. is also developing AM0010 with anti-PD-1 immune checkpoint inhibitor that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, as well as that is in Phase I/Ib clinical trial for the treatment of renal cell carcinoma, and melanoma and other solid tumors. We show 3 historical shares outstanding datapoints in our coverage of ARMO's shares outstanding history.|
Understanding the changing numbers of ARMO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ARMO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ARMO by allowing them to research ARMO shares outstanding history
as well as any other stock in our coverage universe.